DE69839893D1 - Anti-östrogene Steroide, pharmazeutische Zusammensetzungen und Verwendungen davon - Google Patents

Anti-östrogene Steroide, pharmazeutische Zusammensetzungen und Verwendungen davon

Info

Publication number
DE69839893D1
DE69839893D1 DE69839893T DE69839893T DE69839893D1 DE 69839893 D1 DE69839893 D1 DE 69839893D1 DE 69839893 T DE69839893 T DE 69839893T DE 69839893 T DE69839893 T DE 69839893T DE 69839893 D1 DE69839893 D1 DE 69839893D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
estrogenic steroids
estrogenic
steroids
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839893T
Other languages
English (en)
Inventor
Masato Tanabe
Richard H Peters
Wan-Ru Chao
Ling Jong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Stanford Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc, Stanford Research Institute filed Critical SRI International Inc
Application granted granted Critical
Publication of DE69839893D1 publication Critical patent/DE69839893D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
DE69839893T 1997-12-24 1998-12-23 Anti-östrogene Steroide, pharmazeutische Zusammensetzungen und Verwendungen davon Expired - Lifetime DE69839893D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/998,877 US6054446A (en) 1997-12-24 1997-12-24 Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

Publications (1)

Publication Number Publication Date
DE69839893D1 true DE69839893D1 (de) 2008-09-25

Family

ID=25545637

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69839893T Expired - Lifetime DE69839893D1 (de) 1997-12-24 1998-12-23 Anti-östrogene Steroide, pharmazeutische Zusammensetzungen und Verwendungen davon
DE69812433T Expired - Lifetime DE69812433T2 (de) 1997-12-24 1998-12-23 Anti-estrogene steroide, pharmazeutische zusammensetzungen und verwendungen davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69812433T Expired - Lifetime DE69812433T2 (de) 1997-12-24 1998-12-23 Anti-estrogene steroide, pharmazeutische zusammensetzungen und verwendungen davon

Country Status (14)

Country Link
US (3) US6054446A (de)
EP (4) EP1310509B1 (de)
JP (4) JP2001525855A (de)
KR (1) KR100464739B1 (de)
CN (2) CN101130567B (de)
AU (1) AU749597C (de)
BR (1) BR9814435A (de)
CA (1) CA2281844C (de)
DE (2) DE69839893D1 (de)
HU (1) HUP0100136A3 (de)
IL (1) IL136972A0 (de)
NO (1) NO317978B1 (de)
RU (1) RU2233288C2 (de)
WO (1) WO1999033859A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
EP1253966B1 (de) * 1999-08-13 2011-04-27 Curadis GmbH Substanzen und mittel zur positiven beeinflussung von kollagen
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
WO2001058919A2 (en) * 2000-02-11 2001-08-16 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
US6953785B2 (en) 2000-04-24 2005-10-11 Kyowa Hakko Kogyo Co., Ltd. Estra-1,3,5(10)-triene derivatives
WO2001099009A2 (en) * 2000-06-20 2001-12-27 United States Postal Service Systems and methods for electronic message content identification
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2287184T3 (es) * 2000-11-03 2007-12-16 Washington University Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora.
CA2430100A1 (en) * 2000-11-27 2002-05-30 Entremed, Inc. Antiangiogenic agents
JP2002241395A (ja) * 2001-02-16 2002-08-28 Taiho Yakuhin Kogyo Kk エストラ−４，６−ジエン−３，１７−ジオンの製造方法
US20050079156A1 (en) * 2001-11-06 2005-04-14 Grace Wong Method of treating endometreosis
IL161762A0 (en) * 2001-11-06 2005-11-20 Applied Research Systems Estradiol inhibiting agents in breast cancer
BRPI0306736B8 (pt) * 2002-01-21 2021-05-25 Akzo Nobel Nv processo para a preparação de 7alfa-metilesteróides, e, composto
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
US20050095241A1 (en) * 2003-08-26 2005-05-05 Vadlamudi Ratna K. Estrogen receptor modulators and uses thereof
AU2005222934B2 (en) 2004-03-12 2010-06-17 Entremed, Inc. Antiangiogenic agents
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
TW200740442A (en) * 2005-08-29 2007-11-01 Taiho Pharmaceutical Co Ltd Therapeutic agent for hypertension
US7935838B2 (en) * 2005-10-27 2011-05-03 Sri International Process for production of steroid compound
WO2007109312A2 (en) 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
CA2702710C (en) 2007-10-16 2013-05-07 Repros Therapeutics, Inc. Trans-clomiphene for metabolic syndrome
SG2014008171A (en) 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US8268807B2 (en) * 2010-04-19 2012-09-18 Sri International Compositions and method for the treatment of multiple myeloma
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US20130123222A1 (en) * 2011-11-10 2013-05-16 Sri International, Inc. Synergistic Anti-Cancer Activity of SR16388 with Anti-Mitotic Drugs
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
ES2681023T3 (es) 2012-02-29 2018-09-11 Repros Therapeutics Inc. Terapia de combinación para tratar el déficit de andrógenos
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JPWO2017010515A1 (ja) 2015-07-14 2018-07-05 ノーベルファーマ株式会社 エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
WO2017096025A1 (en) 2015-12-02 2017-06-08 Helix Twelve Pharmaceuticals Corporation, Inc. Norpregnane derivatives for the risk reduction of breast cancer
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN107805247B (zh) * 2017-10-31 2020-09-29 上海长征富民金山制药有限公司 一种用于制备抗肾纤维化药物和/或抗慢性肾病药的β-咔啉化合物的制备工艺及其应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE84180C (de) *
FR943462A (fr) * 1946-03-08 1949-03-09 Ford Dispositif d'évacuation de l'eau pour glaces de voiture automobile
US2666769A (en) * 1952-09-27 1954-01-19 Searle & Co 17-glycolyl-estradiols
US2840581A (en) * 1956-12-17 1958-06-24 Upjohn Co Carbonyloxy steroids
BE634065A (de) * 1962-06-25 1900-01-01
FR3031M (fr) 1963-05-08 1964-12-28 Roussel Uclaf Nouveau médicament notamment pour le traitement de l'hypercholestérolémie et des troubles en résultant.
FR1453210A (fr) 1963-05-08 1966-06-03 Roussel Uclaf Nouveaux aminostéroïdes et procédé de préparation
FR3012M (fr) * 1963-05-13 1964-12-21 Roussel Uclaf Nouveaux médicaments doués notamment d'activité hypocholestérolémiante.
US3271426A (en) * 1963-06-28 1966-09-06 Schering Corp Novel androstane oximino ethers and methods for their manufacture
NL125069C (de) * 1963-12-24
FR1512326A (fr) * 1964-03-27 1968-02-09 Roussel Uclaf Nouveaux stéroïdes azotés et procédé de préparation
US3271392A (en) * 1965-09-14 1966-09-06 American Home Prod 17alpha-[3'-furyl]-estrogens
US3318917A (en) * 1965-11-12 1967-05-09 Searle & Co 17alpha-(4-alkoxy-3-buten-1-ynyl)estra-1, 3, 5(10)-triene-3, 17beta-diols and derivatives thereof
US3405147A (en) * 1966-02-25 1968-10-08 Searle & Co 17-phenylaliphatylestra-1, 3, 5(10)-trien-3-ols, 16-dehydro derivatives correspondingand esters thereof
US3398138A (en) * 1966-05-24 1968-08-20 American Home Prod Novel cardenolides and derivatives
US3448126A (en) * 1967-02-27 1969-06-03 Searle & Co 3-oxygenated 19-norpregna-1,3,5(10),17(20)-tetraen-21-als and enol esters thereof
US3536703A (en) * 1968-09-11 1970-10-27 Searle & Co N - (3 - alkoxy - 19 - norpregna - 1,3,5(10),17(20) - tetraen - 21 - yl)amines and derivatives thereof
GB1305752A (de) * 1970-03-06 1973-02-07
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
BE787343A (fr) * 1971-08-10 1973-02-09 Hoffmann La Roche Procede pour la preparation de 17-(2-halogenoethylidene)- steroides
US3927046A (en) * 1972-12-09 1975-12-16 Akzona Inc Novel 11,11-alkylidene steroids
US3859365A (en) * 1973-07-19 1975-01-07 Eastman Kodak Co Production of alkyl-substituted phenols from cyclohexenones
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
US5274089A (en) * 1985-10-18 1993-12-28 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
WO1987002367A2 (en) * 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
DE3925507A1 (de) * 1989-07-28 1991-01-31 Schering Ag 14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
DK0471612T3 (da) * 1990-08-14 1999-02-22 Hoechst Marion Roussel Inc Nye 19-nor steroider med carbonkæde omfattende en amidgruppe i 11-beta-stillingen, fremgangsmåde til deres fremstilling, de
DE4132182A1 (de) * 1991-09-24 1993-03-25 Schering Ag 11(beta)-substituierte 14, 17-ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
FR2685332A1 (fr) * 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
WO1993018006A1 (en) 1992-03-11 1993-09-16 Narhex Limited Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
TW303299B (de) 1993-07-22 1997-04-21 Lilly Co Eli
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5447941A (en) 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5446053A (en) 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5593987A (en) 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел

Also Published As

Publication number Publication date
HUP0100136A2 (hu) 2001-08-28
DE69812433T2 (de) 2004-02-12
DE69812433D1 (de) 2003-04-24
CN101130567A (zh) 2008-02-27
KR20000075580A (ko) 2000-12-15
EP1310509B1 (de) 2008-08-13
EP1847548A2 (de) 2007-10-24
JP4959276B2 (ja) 2012-06-20
CN101130567B (zh) 2011-11-23
US6455517B1 (en) 2002-09-24
JP2007269797A (ja) 2007-10-18
EP1847548A3 (de) 2012-09-12
EP1056768A2 (de) 2000-12-06
AU749597C (en) 2003-02-20
CN1332974C (zh) 2007-08-22
JP3968114B2 (ja) 2007-08-29
US6054446A (en) 2000-04-25
JP2007051148A (ja) 2007-03-01
EP2305694A3 (de) 2013-04-17
HUP0100136A3 (en) 2002-04-29
EP1310509A2 (de) 2003-05-14
US6281205B1 (en) 2001-08-28
JP4718512B2 (ja) 2011-07-06
IL136972A0 (en) 2001-06-14
JP2001525855A (ja) 2001-12-11
NO20003254D0 (no) 2000-06-22
BR9814435A (pt) 2004-08-10
CA2281844C (en) 2007-06-19
EP1310509A3 (de) 2004-12-08
CA2281844A1 (en) 1999-07-08
RU2233288C2 (ru) 2004-07-27
EP2305694A2 (de) 2011-04-06
WO1999033859A3 (en) 1999-12-23
NO20003254L (no) 2000-08-21
WO1999033859A2 (en) 1999-07-08
EP1056768B1 (de) 2003-03-19
US20020032181A1 (en) 2002-03-14
AU2010499A (en) 1999-07-19
AU749597B2 (en) 2002-06-27
JP2007031446A (ja) 2007-02-08
NO317978B1 (no) 2005-01-17
WO1999033859A9 (en) 1999-09-23
KR100464739B1 (ko) 2005-01-05
CN1291196A (zh) 2001-04-11

Similar Documents

Publication Publication Date Title
DE69839893D1 (de) Anti-östrogene Steroide, pharmazeutische Zusammensetzungen und Verwendungen davon
DE69822209D1 (de) ESTRON-SULFatase HEMMENDE ESTRON-SULFAMATVERBINDUNGEN, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
FI991485A (fi) Uusi farmaseuttinen koostumus
DK1135139T3 (da) Præparater indeholdende mikroniseret eplerenon
ID27415A (id) Komposisi farmaseutik
NO20005913D0 (no) Legemiddelsammensetning
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
ATE353909T1 (de) 3-stickstoff-6,7-dioxygenierte steroid verbindungen und verwendungen davon
IL146230A0 (en) 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ATE245026T1 (de) 2-phenyl-1-(-(2-aminoethoxy)-benzyl -indol und estrogen als kombinationpräparate
ID27201A (id) Komposisi farmasi
ID27150A (id) Sediaan levotiroksin bahan farmasi
ATE205217T1 (de) Steroide als mittel zur kontrazeption und gegen osteoporose
DE69830154D1 (de) Pharmazeutische zusammensetzungen
IT1304190B1 (it) Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
ATE228839T1 (de) Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen
ID25857A (id) Komposisi farmasi
EE9800209A (et) Antiglükokortikoidne ravimaine
DE60040851D1 (de) N und einrichtung zu dessen herstellung
ID26215A (id) Komposisi farmasi
DE69813624D1 (de) Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
DE69900336D1 (de) Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen
ID23531A (id) Komposisi farmasi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition